FDA Inspection 1258283 — Hybio Pharmaceutical (Wuhan) Co., Ltd.
The FDA completed an inspection of Hybio Pharmaceutical (Wuhan) Co., Ltd. on Nov 29, 2024 in Wuhan. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 29, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)